Who
Allan Reine
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Prime Medicine; Chief Financial Officer, Foghorn Therapeutics; Chief Financial Officer, Palvella Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 3
- Sells
- 0
- Bought
- $461K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 9 Aug 2017
- Last trade
- 26 Feb 2026
- Last filed
- 27 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 27 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —850,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 | filing |
| 21 May 2025filed 22 May 2025 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $148K125,000 at $1.18 | filing |
| 19 May 2025filed 19 May 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 27 Feb 2025filed 3 Mar 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 5 Dec 2024filed 9 Dec 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 26 Jan 2022filed 28 Jan 2022 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 9 Aug 2021filed 11 Aug 2021 | FHTX Foghorn TherapeuticsBiotechnology | SEC FORM 4 Code M | $100K26,892 at $3.72 | filing |
| 9 Aug 2021filed 11 Aug 2021 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,892 at $0.00 | filing |
| 28 Jan 2021filed 1 Feb 2021 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 26 Feb 2019filed 28 Feb 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,500 at $0.00 | filing |
| 20 Feb 2018filed 26 Feb 2018 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,833 at $0.00 | filing |
| 20 Feb 2018filed 26 Feb 2018 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Aug 2017filed 17 Aug 2017 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Bought | $98K20,000 at $4.89 | filing |
News
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in StockPVLA · tickerreport.com · 17 Oct 2026Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePVLA · manilatimes.net · 15 Oct 2026Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in StockPVLA · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Allan Reine; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.